FTSE MIB
34.244,28 -26,84 (-0,08%) Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
83,20 +0,39 (+0,47%) Bitcoin EUR
59.518,64 -2.553,04 (-4,11%)
Fate Therapeutics, Inc. (FATE)
Dopo ore:
| Chiusura precedente | 4,5400 |
| Aperto | 4,5900 |
| Denaro | 4,2900 x 500 |
| Lettera | 4,3200 x 1000 |
| Min-Max giorno | 4,1700 - 4,6600 |
| Intervallo di 52 settimane | 1,6300 - 8,8300 |
| Volume | |
| Media Volume | 2.762.974 |
| Capitalizzazione | 489,267M |
| Beta (5 anni mensile) | 1,68 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,6400 |
| Prossima data utili | 01 mag 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 7,80 |
GlobeNewswireFate Therapeutics to Present at Upcoming September Investor Conferences
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 18th Annual BioPharma Conference on Thursday, September 7
- GlobeNewswire
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy 2H23 IND Submission Planned under ONO Collaboration for FT825/ONO-8250; HER2-targeted CAR T-cell Program Incorporates Seven Novel Synthetic Controls Designed to Overcome Unique Challenges in Treating Solid Tumors Dose Escalation Ongoing in Phase 1 Studies of FT819 CD19-targeted 1XX CAR T-
- GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023 at 5:00 PM ET to report its second quarter 2023 fin
